Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / AstronauTx appoints new CMO and VP
Business executive appointment

AstronauTx appoints new CMO and VP

Analysis based on 6 articles · First reported May 12, 2026 · Last updated May 15, 2026

Sentiment
40
Attention
2
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The appointments of Dr. Michelle Mellion and Deb Gouveia are expected to strengthen AstronauTx's clinical development capabilities, potentially accelerating its pipeline of Alzheimer's disease therapeutics. This could lead to increased investor confidence in AstronauTx and the broader biotechnology sector focused on neurological disorders.

biotechnology pharmaceuticals
Event Summary

AstronauTx, a biotechnology company focused on treating Alzheimer's Disease and other neurological disorders, announced the appointments of Dr. Michelle Mellion as Chief Medical Officer (CMO) and Deb Gouveia as Vice President, Clinical Operations and Development Strategy. Dr. Michelle Mellion brings over two decades of experience from companies like PepGen, BeOne Medicines, Biogen, Vertex Pharmaceuticals, and Fulcrum Therapeutics, and will lead AstronauTx's clinical strategy. Deb Gouveia adds over 25 years of experience in clinical operations. These strategic hires are crucial as AstronauTx prepares to advance its lead programs into clinical development, aiming to leverage sleep architecture modulation as a disease-modifying strategy.

Key Actions
100 AstronauTx appointed Michelle Mellion
80 AstronauTx appointed Deb Gouveia
Entities Involved
priv
AstronauTx
AstronauTx appointed Dr. Michelle Mellion as Chief Medical Officer and Deb Gouveia as Vice President, Clinical Operations and Development Strategy, strengthening its clinical development capabilities as it prepares to advance its lead programs into clinical development.
Importance 100 Sentiment 50
per
Michelle Mellion
Dr. Michelle Mellion was appointed Chief Medical Officer at AstronauTx, where she will lead clinical strategy and development activities, leveraging her two decades of experience in neurology and clinical development.
Importance 90 Sentiment 40
per
Deb Gouveia
Deb Gouveia was appointed Vice President, Clinical Operations and Development Strategy at AstronauTx, bringing over 25 years of experience in building and leading clinical operations and development infrastructure.
Importance 70 Sentiment 30
loc
Greece — Rhodes
Greece — Rhodes, CEO of AstronauTx, commented on the importance of Dr. Michelle Mellion's and Deb Gouveia's appointments for strengthening the company's clinical capabilities.
Importance 20 Sentiment 0
stock
PepGen
Dr. Michelle Mellion previously held a Chief Medical Officer role at PepGen, leading clinical development efforts.
Importance 10 Sentiment 0
priv
BeOne Medicines
Dr. Michelle Mellion previously held a Chief Medical Officer role at BeOne Medicines, leading clinical development efforts.
Importance 10 Sentiment 0
stock
Biogen
Dr. Michelle Mellion previously held positions at Biogen, contributing to programs spanning remyelination.
Importance 10 Sentiment 0
stock
Vertex Pharmaceuticals
Dr. Michelle Mellion previously held positions at Vertex Pharmaceuticals, contributing to programs spanning pain.
Importance 10 Sentiment 0
stock
Fulcrum Therapeutics
Dr. Michelle Mellion previously held positions at Fulcrum Therapeutics, contributing to programs spanning facioscapulohumeral muscular dystrophy (FSHD).
Importance 10 Sentiment 0
stock
Novartis
Novartis led AstronauTx's £48 million/$61 million Series A financing in October 2023.
Importance 5 Sentiment 0
priv
SV Health Investors
SV Health Investors' Dementia Discovery Fund founded AstronauTx and participated in its Series A financing.
Importance 5 Sentiment 0
priv
MPM BioImpact
MPM BioImpact participated in AstronauTx's Series A financing.
Importance 5 Sentiment 0
priv
Brandon Capital
Brandon Capital participated in AstronauTx's Series A financing.
Importance 5 Sentiment 0
stock
Tiziana Life Sciences
Tiziana Life Sciences participated in AstronauTx's Series A financing.
Importance 5 Sentiment 0
stock
Bristol Myers Squibb
Bristol Myers Squibb participated in AstronauTx's Series A financing.
Importance 5 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.